Kezar Life Sciences, Inc. (KZR)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Kezar Life Sciences, Inc. (KZR)

Company Performance

Current Price

as of Oct 18, 2024

$0.82

P/E Ratio

N/A

Market Cap

$60.11M

Description

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Metrics

Overview

HQSouth San Francisco, CA
SectorHealth Technology
IndustryBiotechnology
TickerKZR
Price$0.8238+0.96%

Trading Information

Market Cap$60.11M
Float85.06%
Average Daily Volume (1m)2,050,669
Average Daily Volume (3m)846,103
EPS-$1.35

Company

Revenue$7.00M
Rev Growth (1yr)N/A
Net Income-$21.55M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$21.64M

EV-$102.86M
EV/Revenue-14.69
P/EN/A
P/S8.57
P/B0.40

Documents

Earnings Calls

Earnings Report 2020Q2

Earnings Report (2020-08-09)

Factset

Factset Business Description

Factset Street Account

Kezar Life Sciences reports Q3 EPS ($0.32) vs FactSet ($0.36) [5 est, ($0.37)-(0.33)] ($0.75, 0.00) (2023-11-13T21:02:49Z)

Follow-up: Kezar Life Sciences announces strategic restructuring to prioritize clinical-stage assets; appoints Christopher Kirk as CEO ($1.05, 0.00) (2023-10-03T20:13:45Z)